Literature DB >> 23053156

[Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer].

M Bremer1.   

Abstract

Entities:  

Year:  2012        PMID: 23053156     DOI: 10.1007/s00066-012-0219-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  3 in total

1.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Authors:  Kelly L Bolton; Georgia Chenevix-Trench; Cindy Goh; Siegal Sadetzki; Susan J Ramus; Beth Y Karlan; Diether Lambrechts; Evelyn Despierre; Daniel Barrowdale; Lesley McGuffog; Sue Healey; Douglas F Easton; Olga Sinilnikova; Javier Benítez; María J García; Susan Neuhausen; Mitchell H Gail; Patricia Hartge; Susan Peock; Debra Frost; D Gareth Evans; Rosalind Eeles; Andrew K Godwin; Mary B Daly; Ava Kwong; Edmond S K Ma; Conxi Lázaro; Ignacio Blanco; Marco Montagna; Emma D'Andrea; Maria Ornella Nicoletto; Sharon E Johnatty; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Ellen L Goode; Brooke L Fridley; Jennifer T Loud; Mark H Greene; Phuong L Mai; Angela Chetrit; Flora Lubin; Galit Hirsh-Yechezkel; Gord Glendon; Irene L Andrulis; Amanda E Toland; Leigha Senter; Martin E Gore; Charlie Gourley; Caroline O Michie; Honglin Song; Jonathan Tyrer; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Ulf Kristoffersson; Håkan Olsson; Åke Borg; Douglas A Levine; Linda Steele; Mary S Beattie; Salina Chan; Robert L Nussbaum; Kirsten B Moysich; Jenny Gross; Ilana Cass; Christine Walsh; Andrew J Li; Ronald Leuchter; Ora Gordon; Montserrat Garcia-Closas; Simon A Gayther; Stephen J Chanock; Antonis C Antoniou; Paul D P Pharoah
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

Review 2.  BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.

Authors:  William D Foulkes
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

3.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Authors:  Bryan T J Hennessy; Kirsten M Timms; Mark S Carey; Alexander Gutin; Larissa A Meyer; Darl D Flake; Victor Abkevich; Jennifer Potter; Dmitry Pruss; Pat Glenn; Yang Li; Jie Li; Ana Maria Gonzalez-Angulo; Karen Smith McCune; Maurie Markman; Russell R Broaddus; Jerry S Lanchbury; Karen H Lu; Gordon B Mills
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.